Article Text

PDF
Fibrosis biomarkers in isolated Raynaud's phenomenon: too little, too soon?
  1. Francesca Ingegnoli1,
  2. Roberta Gualtierotti1,
  3. Tommaso Schioppo1,
  4. Annalisa Orenti2,
  5. Patrizia Boracchi2,
  6. Chiara Lubatti1,
  7. Claudio Mastaglio3,
  8. Valentina Galbiati3,
  9. Antonella Murgo1,
  10. Silvana Zeni1,
  11. Claudia Grossi4,
  12. Orietta Borghi4,
  13. William Rosenberg5,
  14. Laura Castelnovo6,
  15. Luigi Meroni Pier1,4
  1. 1 Department of Clinical Science & Community Health, Division of Rheumatology, Istituto Gaetano Pini, University of Milano, Milano, Italy
  2. 2 Department of Clinical Science & Community Health, Medical Statistics and Biometry, University of Milano, Milano, Italy
  3. 3 Rheumatology Unit, Ospedale Moriggia-Pelascini, Gravedona, Italy
  4. 4 Research Laboratory on Immuno-Rheumatology, IRCCS Istituto Auxologico Italiano, Milano, Italy
  5. 5 Division of Medicine, Institute for Liver and Digestive Health, University College London, Royal Free Campus, London, UK
  6. 6 Dipartimento Medico, U.O.C. Medicina Interna, Presidio Ospedaliero di Saronno, Saronno, Italy
  1. Correspondence to Dr Ingegnoli Francesca, Department of Clinical Science & Community Health, Division of Rheumatology, Istituto Gaetano Pini, University of Milano, Piazza Cardinal Ferrari 1, Milano 20122, Italy; francesca.ingegnoli{at}unimi.it

Statistics from Altmetric.com

Raynaud's phenomenon (RP) can be the first manifestation or may be present before the development of an overt systemic sclerosis (SSc).1

Enhanced liver fibrosis (ELF) test, an algorithm combining tissue inhibitors of matrix metalloproteinases (TIMP-1), hyaluronic acid (HA) and aminoterminal propeptide of type III procollagen (PIIINP), has been related to several measures of fibrosis in SSc patients.24

We evaluated whether these biomarkers could discriminate between primary and secondary RP.

Consecutive adult patients with RP at the first rheumatologic evaluation were recruited from February 2011 to May 2012 with ethics committee approval. Exclusion criteria were history of any fibrosing disorder, organ transplantation, hepatocellular carcinoma or treatment with interferon. One patient was excluded for interferon treatment. Fifteen limited cutaneous SSc and 15 diffuse …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.